Optimi Health Corp OPTH

$OPTH - One to Watch The company is advancing a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD, planned for 2027 with up to 100 veterans and frontline workers. Psychedelic medicine is heating up — and OPTH is positioning early. Communicated disclaimer - https://stockresearchtoday.com/opth/

$OPTH IS A BULLISH WEDGE BUILDING ? 📈 Optimi Health continues to tighten inside a bullish wedge, with price compressing toward the apex. 🔹 $5.58 first key level to reclaim 🔹 $6.18 ➡️ $6.57 next resistance zone 🔹 $8.42 becomes the major level above 🔹 Breakout with volume could confirm the move OPTH has a Health Canada authorized Phase 2 psilocybin trial for up to 200 patients and Phase 3 MDMA trial for up to 100 patients. Even more interesting, Optimi is already commercially supplying psilocybin and MDMA while advancing both clinical programs. Communicated Disclaimer: https://stockresearchtoday.com/opth/ Sector Peers: $CMPS $ATAI $GHRS $DFTX

$OPTH coiling for a move 👀📈 Weekly symmetrical triangle forming since June, and price is squeezing right into the apex. Breakout map: 🔓 Break + hold $5.10 - triangle breakout 🎯 $6.07 - first target (old support) 🏔️ $8.91 - range high back in play And the fundamentals back it up: ✅ Already generating revenue in Australia ✅ Health Canada GMP + export licences ✅ UK psilocybin export for a Phase 2 trial ✅ Phase 3 MDMA-PTSD trial planned for 2027 ✅ CEO bought shares on the open market Revenue + a tightening chart = one I'm watching closely CommunicatedDisclaimer:http://stockresearchtoday.com/opth/

NASDAQ: $OPTH | Optimi Health Corp. *Sponsored Float: 4.5M and holding the EMA here. Optimi Health develops regulated psychedelic medicines, including psilocybin and MDMA, and is already supplying psilocybin into Australia’s regulated treatment market. Upcoming Catalysts: • Phase 2 psilocybin trial planned for 2027 • Phase 3 MDMA/PTSD study planned for 2027 • Continued commercial expansion and international supply With a small float and multiple clinical milestones ahead, $OPTH is one to keep on the radar. Communicated Disclaimer https://stockresearchtoday.com/opth/

🚨 $OPTH | PSYCHEDELICS WITH REAL REVENUE This is one psychedelic biotech I'm watching closely🍄 Most psychedelic names are still stuck in trials. $OPTH is already selling. Optimi isn't just building a pipeline. It's building the manufacturing infrastructure behind the entire psychedelic medicine industry. Here's what stands out: • Finished-dose psilocybin + MDMA capsules • Commercial supply live under Australia's Authorized Prescriber Scheme • Health Canada GMP manufacturing + export licences • Psilocybin exported to the UK for a planned Phase 2 trial • Phase 3 MDMA-PTSD trial planned for 2027 • $15M raised in its 2026 Nasdaq uplisting 💰 • Potential U.S. access if rescheduling happens 💥Next catalysts: Clinical progress, revenue growth, regulatory wins and new markets. CommunicatedDisclaimer:http://stockresearchtoday.com/opth/

$OPTH ONE PSYCHEDELIC NAME WORTH WATCHING Optimi Health is a Canadian pharmaceutical company producing GMP grade psilocybin and MDMA for regulated mental health treatments and clinical trials. Recent milestones are stacking up: 🔹 200 patients targeted in its Health Canada authorized Phase 2 psilocybin trial for Major Depressive Disorder 🔹 100 patients planned for its Phase 3 MDMA trial targeting PTSD in veterans and frontline workers 🔹 Latest batch of 5mg psilocybin capsules completed and quality released for clinical + commercial use 🔹 Commercial psychedelic supply already reaching regulated markets including Canada + Australia With 100M+ people estimated to suffer from treatment resistant depression and 300M+ from PTSD globally, the addressable patient population is significant. The global psychedelic drugs market is estimated at $2.04B in 2026 and projected to reach $5.16B by 2034 💰 Communicated Disclaimer: https://stockresearchtoday.com/opth/ Sector Peers : $CMPS $ATAI $GHRS

NASDAQ: $OPTH Optimi Health Corp. *Sponsored Float is only 4.562M and hold the EMA here. Optimi Health is a commercial-stage pharmaceutical manufacturer focused on regulated psychedelic medicines, including psilocybin and MDMA, for mental-health treatment programs. The company is already supplying finished-dose psilocybin into Australia’s regulated treatment market and has expanded internationally through clinical and commercial shipments. Several potential catalysts are developing: • Phase 2 Psilocybin Trial: Health Canada has authorized a trial in up to 200 patients with major depressive disorder, planned to begin in the first half of 2027. • Phase 3 MDMA Trial: Optimi plans to begin a Health Canada-authorized Phase 3 study in 2027 evaluating MDMA-assisted therapy for PTSD in up to 100 veterans and frontline workers. • Commercial Expansion: Optimi recently completed another production batch that will supply both its Canadian Phase 2 program and commercial treatment-resistant depression patients in Australia. With multiple clinical programs advancing, existing commercial supply activity and a relatively small float, OPTH is one to keep on the radar as these 2027 milestones approach. Communicated Disclaimer https://stockresearchtoday.com/opth/

Optimi Health Corp. (NASDAQ: $OPTH; also CSE: $OPTI) is a small-cap Canadian pharmaceutical manufacturer focused on GMP-grade psychedelic drug products. https://x.com/whiskey_lima729/status/2104552685110169891?s=46